Skip to main content
. 2023 Jul 20;65:102822. doi: 10.1016/j.redox.2023.102822

Fig. 7.

Fig. 7

Butyrate reduces the ferroptosis resistance of CSCs. a, The luminal-to-crypt gradient of butyrate in the large intestine. b, The expression of xCT in LGR5+ and LGR5- non-CSCs were evaluated by analyzing a GEO dataset (GSE92961). c, The expression of xCT in CD133+ CSCs and CD133- non-CSCs in CRC patients were evaluated by analyzing a single-cell sequencing dataset (GSE146771). d, The expression of LGR5 was evaluated in AOM/DSS CRC tissues by qPCR. e, The viability of colon organoids isolated from AOM/DSS CRC mice administered with butyrate, erastin or in combination were evaluated by MTT assay. f, CRC organoids were treated with erastin (10 μM), butyrate (0.5 mM), or both for 24 h. The expression of LGR5 was evaluated by qPCR. g, HCT116 CSC spheres were treated with erastin (20 μM), butyrate (0.5 mM), or both for 24 h. The viability was examined by PI staining. h, The expression of CD133 was evaluated by qPCR. Data are represented as the mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001, two-tailed unpaired Student's t-test.